Form 8-K - Current report:
SEC Accession No. 0001193125-24-161593
Filing Date
2024-06-14
Accepted
2024-06-14 16:05:55
Documents
13
Period of Report
2024-06-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d765804d8k.htm   iXBRL 8-K 29065
  Complete submission text file 0001193125-24-161593.txt   155128

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA oric-20240612.xsd EX-101.SCH 2859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20240612_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20240612_pre.xml EX-101.PRE 11713
16 EXTRACTED XBRL INSTANCE DOCUMENT d765804d8k_htm.xml XML 3779
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 241044730
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)